Tilapia production has significantly increased over the past few years due to the adoption of semi-intensive and intensive aquaculture technologies. However, these farming systems have subjected the fish to stressful conditions that suppress their immunity, hence exposing them to various pathogens. The application of antibiotics and therapeutics to enhance disease resistance, survival, and growth performance in aquaculture has been recently banned due to the emergence of antibiotic-resistant bacteria that pose a serious threat to the environment and consumers of aquatic organisms. Hence, the need for an alternative approach based on sustainable farming practices is warranted. Probiotic, prebiotic, and synbiotic use in tilapia production is considered a viable, safe, and environmentally friendly alternative that enhances growth performance, feed utilization, immunity, disease resistance, and fish survival against pathogens and environmental stress. Their inclusion in fish diets and or rearing water improves the general wellbeing of fish. Hence, this review aims at presenting research findings from the use of probiotics, prebiotics, and synbiotics and their effect on survival, growth, growth performance, gut morphology, microbial abundance, enzyme production, immunity, and disease resistance in tilapia aquaculture, while highlighting several hematological, blood biochemical parameters, and omics techniques that have been used to assess fish health. Furthermore, gaps in existing knowledge are addressed and future research studies have been recommended.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12602-021-09852-x | DOI Listing |
Health Syst Reform
December 2025
Independent Consultant, Alexandria, VA, USA.
For over 50 years, health systems the world over have failed people with type 2 diabetes mellitus (T2DM). The WHO documents a quadrupling of people with diabetes in a 34-year period to 422 million in 2014, the overwhelming majority of whom were T2DM. This happened despite extensive scientific literature on the causes of, as well as proven treatments for, this disease.
View Article and Find Full Text PDFEur J Prev Cardiol
January 2025
Department of Cardiology, Kailuan General Hospital, Tangshan 063001, Hebei, CN.
Background: The precise pathways connecting insulin resistance (IR) to atherosclerotic cardiovascular disease (ASCVD) remain undefined. The present study aimed to examine the mediating role of arterial stiffness in the association between IR and ASCVD, providing epidemiology insights into the potential mechanisms driving IR to incident ASCVD.
Methods: A total of 59,777 participants from the Kailuan Study Arterial Stiffness Subcohort who were free of ASCVD at baseline were enrolled in the present study.
PLoS One
January 2025
Veterinary School, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Salmonella Dublin is a serovar that causes severe infections and cattle. Despite the importance of this agent, research on achieving its elimination from dairy farms is limited, which complicates risk mitigation and control efforts. This study thus aimed to assess the prevalence of S.
View Article and Find Full Text PDFPaediatr Drugs
January 2025
Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Despite significant global reductions in cases of pneumonia during the last 3 decades, pneumonia remains the leading cause of post-neonatal mortality in children aged <5 years. Beyond the immediate disease burden it imposes, pneumonia contributes to long-term morbidity, including lung function deficits and bronchiectasis. Viruses are the most common cause of childhood pneumonia, but bacteria also play a crucial role.
View Article and Find Full Text PDFAnn Hematol
January 2025
Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!